From pharmacogenetics to pharmaco-omics: Milestones and future directions.
Détails
![Ressource 1](https://serval.unil.ch/static/img/forbidden.png)
Accès restreint UNIL
Etat: Public
Version: de l'auteur⸱e
Licence: CC BY 4.0
ID Serval
serval:BIB_4359AD13D7C0
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
From pharmacogenetics to pharmaco-omics: Milestones and future directions.
Périodique
HGG advances
ISSN
2666-2477 (Electronic)
ISSN-L
2666-2477
Statut éditorial
Publié
Date de publication
14/04/2022
Peer-reviewed
Oui
Volume
3
Numéro
2
Pages
100100
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Publication Status: epublish
Résumé
The origins of pharmacogenetics date back to the 1950s, when it was established that inter-individual differences in drug response are partially determined by genetic factors. Since then, pharmacogenetics has grown into its own field, motivated by the translation of identified gene-drug interactions into therapeutic applications. Despite numerous challenges ahead, our understanding of the human pharmacogenetic landscape has greatly improved thanks to the integration of tools originating from disciplines as diverse as biochemistry, molecular biology, statistics, and computer sciences. In this review, we discuss past, present, and future developments of pharmacogenetics methodology, focusing on three milestones: how early research established the genetic basis of drug responses, how technological progress made it possible to assess the full extent of pharmacological variants, and how multi-dimensional omics datasets can improve the identification, functional validation, and mechanistic understanding of the interplay between genes and drugs. We outline novel strategies to repurpose and integrate molecular and clinical data originating from biobanks to gain insights analogous to those obtained from randomized controlled trials. Emphasizing the importance of increased diversity, we envision future directions for the field that should pave the way to the clinical implementation of pharmacogenetics.
Mots-clé
biobanks, bioinformatics, causal inference, electronic health records, genome-wide association studies, multi-omics, pharmacogenetics, pharmacogenome, pharmacogenomics
Pubmed
Web of science
Open Access
Oui
Création de la notice
11/04/2022 8:39
Dernière modification de la notice
29/07/2022 6:39